Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111

Sort by

Sort Order Select

Journal Articles

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Lingzhi Yan, Zhi Yan, Jingjing Shang, Xiaolan Shi, Song Jin, Liqing Kang, Su Qu, Jin Zhou, Huizhu Kang, Ruju Wang, Ying Yao, Jing Wang, Weiqin Yao, Guanghua Chen, Lei Yu, Depei Wu, MD PhD, Fu Cheng Cheng, MD PhD

Blood (2019) 134 (Supplement_1): 578.

https://doi.org/10.1182/blood-2019-129740

Published: 2019

Journal Articles

Super factor Va, an Engineered Factor V Molecule, Effectively Reduces Bleeding and Acute Coagulopathy in Mouse Models of Trauma and Shock

Bilgimol Chumappumkal Joseph, PhD, Laurent O Mosnier, Annette von Drygalski, MD PharmD

Blood (2019) 134 (Supplement_1): 1101.

https://doi.org/10.1182/blood-2019-124433

Published: 2019

Journal Articles

Risk Factors of Acute Pancreatitis in Pediatric Acute Lymphoblastic Leukemia Patients: A Single-Center Experience

Soyoon MIN, MD, Hyery Kim, MD, Juhee Shin, Jin Kyung Suh, MD, Sung Han Kang, MD, Kyung-Nam Koh, MD, Ho Joon Im, MD, Jong Jin Seo, MD

Blood (2019) 134 (Supplement_1): 5077.

https://doi.org/10.1182/blood-2019-128236

Published: 2019

Journal Articles

"a Needle in a Haystack". Let´s Talk about Acquired Hemophilia in Pediatrics

German Alejandro Detarsio, Sr., BSc, Mariana Raviola, Mauro Davoli, MD, Maria Fabiana Garcia

Blood (2019) 134 (Supplement_1): 4936.

https://doi.org/10.1182/blood-2019-125977

Published: 2019

Journal Articles

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Eric Huselton, MD, Amanda F Cashen, MD, John F. DiPersio, MD PhD, Meagan Jacoby, MD, Iskra Pusic, MD, Rizwan Romee, MD PhD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD

Blood (2019) 134 (Supplement_1): 3915.

https://doi.org/10.1182/blood-2019-132065

Published: 2019

Journal Articles

Increased Mortality and Bleeding in a Large Cohort of Patients on Heparin Anticoagulation Therapy with Discordant Anti-Factor Xa Activity and Activated Partial Thromboplastin Time (PTT); Implications for Clinical Management

Saurabh Gombar, MD PhD, Derek Boothroyd, PhD, Anandi Krishnan, PhD, Husham Sharifi, MD, Joe Hsu, MD, James Zehnder, MD

Blood (2019) 134 (Supplement_1): 712.

https://doi.org/10.1182/blood-2019-132112

Published: 2019

Journal Articles

Recombinant Activated Coagulation Factor VII (rFVIIa) for Treatment of the Tracheobronchial Bleeding in Mechanically Ventilated (MV) Thrombocytopenic Patients (pts)

Gennadii M. Galstian, Olesya A. Polevodova, MD, Vladimir Yu. Zorenko, MD PhD, Valeriy G. Savchenko, MD PhD

Blood (2018) 132 (Supplement 1): 2446.

https://doi.org/10.1182/blood-2018-99-115685

Published: 2018

Journal Articles

Detection and Differential Diagnosis of Prekallikrein Deficiency: Genetic Study of New Families and Systematic Review of the Literature

Stefano Barco, Stefanie Sollfrank, Alice Trinchero, Luigi Tomao, Barbara Zieger, Johanna A. Kremer Hovinga, MD Prof, Laura Conti, Anke Adenäuer, Erwin Miloni, Karl J. Lackner, Heidi Rossmann, Bernhard Lammle, MD

Blood (2018) 132 (Supplement 1): 2496.

https://doi.org/10.1182/blood-2018-99-116030

Published: 2018

Journal Articles

Overshoot of FVIII Activity in Patients with Acquired Hemophilia

Yoshiyuki Ogawa, MD PhD, Kunio Yanagisawa, MD PhD, Hiroaki Shimizu, MD PhD, Takuma Ishizaki, MD PhD, Akitada Ichinose, MD PhD, Hiroshi Handa, MD PhD

Blood (2018) 132 (Supplement 1): 2497.

https://doi.org/10.1182/blood-2018-99-112126

Published: 2018

Journal Articles

Compound Heterozygous Nonsense Mutations Leading to Hereditary Deficiency of Coagulation Factor XI in a Chinese Pedigree

Qian Li, Hui Zeng, Yong Xu, Min Zhou, Bing Chen, Rong-Fu Zhou, PhD MD

Blood (2018) 132 (Supplement 1): 5032.

https://doi.org/10.1182/blood-2018-99-118105

Published: 2018

Journal Articles

The Molecular Genetic Analysis of Coagulation Factor XI (FXI) Deficiency in Two Chinese Patients

Rong-Fu Zhou, PhD MD, Qian Li, Min Zhou

Blood (2018) 132 (Supplement 1): 5033.

https://doi.org/10.1182/blood-2018-99-118232

Published: 2018

Journal Articles

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

Paul Harker-Murray, MD PhD, Thierry Leblanc, MD, Maurizio Mascarin, Christine Mauz-Körholz, Gerard Michel, MD, Stacy Cooper, MD, Auke Beishuizen, MD PhD, Kasey J. Leger, MD MSc, Alberto Garaventa, Salvatore Buffardi, MD, Laurence Brugieres, MD, Kara M. Kelly, MD, Peter D. Cole, MD, Richard A. Drachtman, Faith Galderisi, DO, Mariana Sacchi, MD, Ying-Ming Jou, Stephen Daw

Blood (2018) 132 (Supplement 1): 927.

https://doi.org/10.1182/blood-2018-99-111279

Published: 2018

Journal Articles

The Isotype of Antiphospholipid Antibodies and Their Associated Risk on Thrombosis and Pregnancy Morbidity; What Are the Odds?

Walid Chayouâ, MSc, Hilde Kelchtermans, PhD, Gary Moore, MD, Jean-Christophe Gris, MD PhD, Jacek Musial, MD PhD, Stéphane Zuily, MDPhD, Bas De Laat, MD, PhD, Katrien Devreese, PhD MD

Blood (2018) 132 (Supplement 1): 1220.

https://doi.org/10.1182/blood-2018-99-113361

Published: 2018

Journal Articles

A Single-Institution Retrospective Study of Causes of Prolonged Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) in the Outpatient Setting

Ryan B. Khodadadi, MD, Joshua P. Slusser, B.S., Diane E. Grill, M.S., Rajiv K. Pruthi, M.B.B.S., Ariela L. Marshall, MD

Blood (2018) 132 (Supplement 1): 2281.

https://doi.org/10.1182/blood-2018-99-109833

Published: 2018

Journal Articles

Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

Ido Paz-Priel, Tiffany Chang, Elina Asikanius, Sammy Chebon, Thomas Emrich, Elena Fernandez, Peter Kuebler, Christophe Schmitt

Blood (2018) 132 (Supplement 1): 633.

https://doi.org/10.1182/blood-2018-99-118492

Published: 2018

Journal Articles

A Normal Prothrombin Time, Activated Partial Thromboplastin Time and Fibrinogen Level Do Not Eliminate Disseminated Intravascular Coagulation (DIC) and Bleeding Risk in Patients with Acute Promyelocytic Leukemia

Kathryn Sarah Simon, PA-C, Prachi Kharkhanis, Catherine R. Caprara, MSN, NP, Stephanie Debragga, Sheldon Bolds, Saleh Alghsoon, Martha L. Arellano, MD, Ravindra Kolhe, MD PhD, Anand Jillella, MD, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 4869.

https://doi.org/10.1182/blood.V130.Suppl_1.4869.4869

Published: 2017

Journal Articles

Results from a Phase 1b (OX1222) Dose-Ranging Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Justin M Watts, MD, Ronan T. Swords, MD PhD FRCPI, FRCPath, Christopher R. Cogle, MD, Gary J. Schiller, MD, Tara L. Lin, MD

Blood (2017) 130 (Supplement 1): 2644.

https://doi.org/10.1182/blood.V130.Suppl_1.2644.2644

Published: 2017

Journal Articles

Thrombotic Risk Factors, Antithrombotic Therapy, and Outcomes of Asymptomatic Carriers of Antiphospholipid Antibodies and Patients with Antiphospholipid Syndrome

Ghaith Abu-Zeinah, MD, Clara Oromendia, MS, Maria Teresa De Sancho, MD

Blood (2017) 130 (Supplement 1): 3710.

https://doi.org/10.1182/blood.V130.Suppl_1.3710.3710

Published: 2017

Journal Articles

Successful Treatment of Bleeding in Acquired Hemophilia A with Activated Prothrombin Complex Concentrate in Spain

Maria Eva Mingot-Castellano, PhD MD, Rocio Pérez-Montes, MD, Mariana Canaro, PhD MD, Ana Marco, PhD MD, Victoria Calle-Gordo, MD, Ana Isabel Heiniger, MD

Blood (2017) 130 (Supplement 1): 3688.

https://doi.org/10.1182/blood.V130.Suppl_1.3688.3688

Published: 2017

Journal Articles

Coagulopathy As a Dose-Limiting Toxicity in Systemic Administration of Mesenchymal Stem Cells (MSCs): Relative Safety of Bone Marrow Versus Adipose Derived MSCs

Xiaowu Wu, MD MSc, Daniel N Darlington, PhD, Robbie K Montgomery, MS, Bin Liu, BS, Jeffrey D Keesee, BS, Josue Garciamarcano, Andres S Penagosnino, Andrew P. Cap, MD PhD

Blood (2017) 130 (Supplement 1): 3654.

https://doi.org/10.1182/blood.V130.Suppl_1.3654.3654

Published: 2017

NARROW

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Super factor Va, an Engineered Factor V Molecule, Effectively Reduces Bleeding and Acute Coagulopathy in Mouse Models of Trauma and Shock

Risk Factors of Acute Pancreatitis in Pediatric Acute Lymphoblastic Leukemia Patients: A Single-Center Experience

"a Needle in a Haystack". Let´s Talk about Acquired Hemophilia in Pediatrics

Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS

Increased Mortality and Bleeding in a Large Cohort of Patients on Heparin Anticoagulation Therapy with Discordant Anti-Factor Xa Activity and Activated Partial Thromboplastin Time (PTT); Implications for Clinical Management

Recombinant Activated Coagulation Factor VII (rFVIIa) for Treatment of the Tracheobronchial Bleeding in Mechanically Ventilated (MV) Thrombocytopenic Patients (pts)

Detection and Differential Diagnosis of Prekallikrein Deficiency: Genetic Study of New Families and Systematic Review of the Literature

Overshoot of FVIII Activity in Patients with Acquired Hemophilia

Compound Heterozygous Nonsense Mutations Leading to Hereditary Deficiency of Coagulation Factor XI in a Chinese Pedigree

The Molecular Genetic Analysis of Coagulation Factor XI (FXI) Deficiency in Two Chinese Patients

Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma

The Isotype of Antiphospholipid Antibodies and Their Associated Risk on Thrombosis and Pregnancy Morbidity; What Are the Odds?

A Single-Institution Retrospective Study of Causes of Prolonged Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) in the Outpatient Setting

Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

A Normal Prothrombin Time, Activated Partial Thromboplastin Time and Fibrinogen Level Do Not Eliminate Disseminated Intravascular Coagulation (DIC) and Bleeding Risk in Patients with Acute Promyelocytic Leukemia

Results from a Phase 1b (OX1222) Dose-Ranging Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Thrombotic Risk Factors, Antithrombotic Therapy, and Outcomes of Asymptomatic Carriers of Antiphospholipid Antibodies and Patients with Antiphospholipid Syndrome

Successful Treatment of Bleeding in Acquired Hemophilia A with Activated Prothrombin Complex Concentrate in Spain

Coagulopathy As a Dose-Limiting Toxicity in Systemic Administration of Mesenchymal Stem Cells (MSCs): Relative Safety of Bone Marrow Versus Adipose Derived MSCs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only